sublicense

sub·li·cense

 (sŭb-lī′səns)
n.
A license giving rights of production or marketing of products or services to a person or company that is not the primary holder of such rights.
tr.v. sub·li·censed, sub·li·cens·ing, sub·li·cens·es
To grant a sublicense to or for.

sub′li·cen·see′ n.

sublicense

(sʌbˈlaɪsəns)
vb (tr)
(of a licence holder) to license (someone else)
Translations
Sublizenz
References in periodicals archive ?
The litigation centered on Acuitas' rights to use and sublicense Arbutus pre-April 15, 2010 LNP technology under a cross license agreement dated November 12, 2012.
M2 EQUITYBITES-November 6, 2017-Xenetic Biosciences signs Right to Sublicense Agreement with Baxalta
M2 PHARMA-November 6, 2017-Xenetic Biosciences signs Right to Sublicense Agreement with Baxalta
VTGN) has signed an exclusive sublicense agreement with BlueRock Therapeutics, a stem cell research company established by Bayer AG and Versant Ventures, for VistaGen's rights to certain proprietary technologies relating to the production of cardiac stem cells for the treatment of heart disease.
In connection with the stock sale, Global Energy Holdings has also agreed to assign to 2020 Energy its sublicense agreement with New Generation Biofuels that grants Global Energy Holdings a sublicense in certain technology related to the production of a vegetable oil based biodiesel.
Under the agreement terms, BMKK will sublicense to DSP the development, manufacturing/marketing and marketing rights of irbesartan, an anti-hypertension drug.
Pursuant to the sublicense agreements, Y's subsidiaries make payments to Y when they reproduce X's computer program on computers and other equipment that they use or when they reproduce and distribute X's computer program on computers and other equipment that they manufacture and market to customers.
Hackensack, NJ), announced that it has entered into agreements with Neurocrine and Wyeth to reorganize the exclusive license from Wyeth to DOV of four compounds and the sublicense by DOV of indiplon to Neurocrine.
Ciphergen sued MAS and LumiCyte in 2000 in response to MAS' accusations of breach of a Technology Transfer Agreement relating to Ciphergen's sublicense of SELDI-TOF MS, which MAS had licensed from the Baylor College of Medicine.
and also has global rights to sublicense it to others.
Soligen, the worldwide licensee of MIT for 3D-Printing Patents in metalcasting, will sublicense Generis' rights to develop, manufacture and market production of chemically set sand molds from computer data.